Re-Importation: A Looming Antitrust Concern for Biotechs?
Executive Summary
With federal legislation to allow drug reimportation mired in the US Senate following passage of a bill in the House of Representatives last year, US biotechs must wrestle with an immediate question: how to prevent their ex-US partners from becoming sources of low-cost imports of their products?